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Abstract
Background: The T-cell mediated immune response plays a central role in the control of malaria after natural infection or
vaccination. There is increasing evidence that T-cell responses are heterogeneous and that both the quality of the immune
response and the balance between pro-inflammatory and regulatory T-cells determines the outcome of an infection. As
Malaria parasites have been shown to induce immunosuppressive responses to the parasite and non-related antigens this
study examined T-cell mediated pro-inflammatory and regulatory immune responses induced by malaria vaccination in
children in an endemic area to determine if these responses were associated with vaccine immunogenicity.
Methods: Using real–time RT- PCR we profiled the expression of a panel of key markers of immunogenecity at different time
points after vaccination with two viral vector vaccines expressing the malaria TRAP antigen (FP9-TRAP and MVA-TRAP) or
following rabies vaccination as a control.
Principal Findings: The vaccine induced modest levels of IFN-c mRNA one week after vaccination. There was also an
increase in FoxP3 mRNA expression in both TRAP stimulated and media stimulated cells in the FFM ME-TRAP vaccine group;
however, this may have been driven by natural exposure to parasite rather than by vaccination.
Conclusion: Quantitative PCR is a useful method for evaluating vaccine induced cell mediated immune responses in frozen
PBMC from children in a malaria endemic country. Future studies should seek to use vaccine vectors that increase the
magnitude and quality of the IFN-c immune response in naturally exposed populations and should monitor the induction of
a regulatory T cell response.
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Introduction
Global mortality and morbidity from Plasmodium falciparum
malaria is high and has risen over the last 20 years, with an
estimated minimum of one million deaths per year [1]. In sub
Saharan Africa the greatest burden lies in children under the age
of five [2,3,4]. Proper implementation of malaria control methods
such as highly effective drugs and insecticide-treated nets could
reduce mortality significantly [5]. However, it seems unlikely that
these measures alone will halt the rising mortality of the disease.
The development of an effective malaria vaccine is viewed as an
effective long term strategy in reducing the burden of this disease
[6]. Although natural immunity to P. falciparum malaria is short
lived [7], strain-specific and develops after repeated exposure [8],
immunisation experiments with irradiated sporozoites have
consistently provided sterile immunity in experimental animals
[9] and human volunteers [10,11]. Immunity does not correlate to
antibody titres against sporozoites and was not generated by
sporozoites made incapable of invading hepatocytes by over-
irradiation [11 12]. T-cell mediated immune responses play an
important role in the control of malaria after natural infection or
after vaccination. In mice, T-cell clones from irradiated sporozoite
immunised mice transfer protective immunity to live sporozoite
challenge [12]. In a large case-control study of Gambian children
the HLA-B*53 allele was associated with protection against severe
malaria [13], suggesting a role for CD8 positive T-cells.
Both pro-inflammatory and regulatory responses to malaria
infection are important in determining the outcome of the disease.
Chronic infection with malaria parasites has been associated with
immunosuppressive responses to the parasite and to unrelated
antigens [14].In animal models of malaria, the release of interferon
gamma (IFN-c) has been shown to mediate protection when
secreted by Plasmodium specific CD8 [15] or CD4 T-cells [16,17].
Following experimental malaria infection of human volunteers,
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was associated with suppression of pro-inflammatory cytokine
responses, faster parasite growth, and induction of
CD4+CD25+FOXP3+ regulatory T-cells (Tregs) [18]. It has been
suggested that Tregs activated during malaria infection suppress
immunity to malaria, by aiding parasite evasion of host immune
responses [19] and may negatively affect naturally acquired
immunity to malaria [20].
In a phase 2b malaria vaccine trial we evaluated the efficacy of a
viral vector vaccine based prime-boost regime (FFM ME-TRAP),
comprising of two vaccinations with an attenuated fowlpox virus
(FP9) then one vaccination with modified vaccinia virus Ankara
(MVA), both recombinant for a pre-erythrocytic antigen construct
containing a multiple-epitope string and thombospondin-related
adhesion protein (ME-TRAP). The trial recruited 1–6 year old
children in the Kilifi district, Kenya and the end-point of the
efficacy trial was clinical malaria. A rabies vaccine was used as the
control in this trial. Over 18 months follow-up, there was no
evidence that FFM ME-TRAP provided protection against
malaria [21,22]. In another study a DNA ME-TRAP and MVA
ME-TRAP vaccine regimen was ineffective at reducing the natural
infection rate in semi-immune African adults in the Gambia [23].
Although the reasons for this lack of efficacy are unclear, it has
been shown that naturally acquired T-cell responses to Pf TRAP
involve the release of competing pro- and anti-inflammatory
cytokines [24].
This study aimed to look at T-cell mediated pro-inflammatory
and regulatory immune responses induced by vaccination in
children in a malaria endemic area to examine whether regulatory
responses could be influencing vaccine immunogenicity in this
setting.
Results
Gene Expression in FFM ME-TRAP Vaccinated Versus
Rabies Vaccinated Children
A total of 88 PBMC samples from 30 children, obtained at
different time points, were thawed for RNA extraction. In the
FFM ME-TRAP group there were no significant differences in the
characteristics of the included versus excluded study subjects
(Table 1). As children with an immune response .100 SFC/10
6
had been preferentially selected for analysis, the IFN-c ELISPOT
immunogenicity was significantly higher in selected versus
excluded subjects. Due to the small size of the rabies vaccine
group (n=10) not all features of excluded subjects were
represented by the included subjects (Table 1).
We profiled vaccine responses by measuring mRNA of IFN-c,
FOXP3, IL-10 and TGF-b1 using real-time RT-PCR and we then
compared gene expression between the FFM ME-TRAP and the
Rabies vaccine groups (Figure 1). In the FFM ME-TRAP group
IFN-c levels showed a trend to elevation at 1 week and 3 months
after the last dose of vaccine with the increased responses
significant at 1 week (P=0.02) when compared with baseline
levels. At 9 months IFN-c expression had returned to baseline
levels. FOXP3 showed a trend to increase at 3 months but these
responses were not significant (P=0.2471) when compared with
the baseline levels. IL-10 and TGF-b1 showed minor differences in
expression across the different time points. In the Rabies group
there were no significant changes in the expression of any gene
tested at any time point. When the responses were compared
between the two groups, only IFN-c expression at 1 week showed
significant response to the vaccine (Table 2).
FOXP3, TGF-b1 and IL-10 responses observed in the FFM
ME- TRAP group were comparable to the ones observed in the
Rabies vaccine group. There was no correlation between the
baseline response of IL-10, FoxP3 or TGF-b1 and IFN-c
responses at 1 week following vaccination (Figure 2A-D).
qPCR Detection of T Cell Clones
Using a mouse T cell clone specific for the H-2Kd-restricted
pb9 CTL epitope (SYIPSAEKI) from the circumsporozoite
protein of P. Berghei we have found that we can detect 250 but
not 25 T cell clones secreting IFN-c in response to pb9 peptide
stimulation when using the qPCR assay (Figure 3A). Using
human PBMC we can detect 20 IFN-c T cells/10
6 PBMC
using the human IFN-c ELISPOT assay [25]. The qPCR assay
may therefore be up to 10 times less sensitive for the detection
of IFN-c T secreting cells when compared to the ELISPOT
assay.
Correlation of qPCR and ELISPOT for the Detection of
IFN-c Is Influenced by HPRT Copy Number of the Tested
Sample
To assess the quality of our qPCR data we sought to correlate
IFN-c mRNA expression with IFN-c protein expression in these
children as determined by the ELISPOT assay [26]. Although
we had preferentially selected children with a positive ELISPOT
response 4 of the 30 children selected had a response ,100
SFC/10
6 PBMC. These 4 children were excluded from the
correlation analysis as we had determined that the sensitivity of
our qPCR assay was between 25 and 250 SFC/10
6 PBMC.
Using the week 1 TRAP stimulated samples we then correlated
IFN-c mRNA and protein expression in the remaining 26
children. No significant correlation was observed using data
from the 26 children (Figure 3B). HPRT is a house keeping gene
expressed at a similar level in all cells. The copy number of
HPRT is therefore an indication of the number of viable cells
present in a sample and the range of HPRT values in our 26
children was from 54 to 80143 copies per sample. To determine
Table 1. Description of subjects selected for qPCR study.
Category Covariate Vaccine Excluded Included
village Mapawa Rabies 31 (16%) 1 (10%)
FFM ME-TRAP 37 (20.4%) 2 (10%)
Junju Rabies 52 (26.8%) 2 (20%)
FFM ME-TRAP 50 (27.6%) 5 (25%)
Mwembe Rabies 16 (8.2%) 0
FFM ME-TRAP 14 (7.7%) 1 (5%)
Gongoni Rabies 43 (22%) 0
FFM ME-TRAP 32 (26.5%) 7 (25%)
kolewa Rabies 52 (26.8%) 7 (70%)
FFM ME-TRAP 48 (26.5%) 5 (25%)
Age Mean Age Rabies 3.6 3.1
(years) FFM ME-TRAP 3.6 3.7
Weight Mean Weight Rabies 12.8 11.6
(kg) FFM ME-TRAP 13.3 13.2
Immunogenicity IFN-c ELISPOT Rabies 1.3 2.1
(log SFC/10
6) FFM ME-TRAP 1.7 2.3
Parasitemia week 1-month 3 Rabies 59 (30.4%) 2 (20%)
FFM 68 (37.6%) 9 (45%)
doi:10.1371/journal.pone.0008434.t001
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be adversely effecting the correlation between IFN-c mRNA
and protein we introduced a cut-off of HPRT copy number
ranging from 50 to 15000 copies per sample. We found that
using samples with an HPRT copy number .6000 we obtained
a significant correlation between IFN-c protein and mRNA
expression (Figure 3B). These results indicate that a minimum
HPRT copy number of 6000 and a minimum ELISPOT
response of 100 SFC/10
6 PBMC is required to demonstrate
correlation of qPCR with ELISPOT responses.
FoxP3 mRNA Expression Is Increased in Subjects
Vaccinated with FFM ME-TRAP
The fold increase in TRAP peptide stimulated over media-
stimulated gene expression showed only an increase in IFN-c gene
expression in the FFM ME-TRAP vaccinated group (Figure 1).
Figure 1. Gene expression analysis over time. Data are presented as a ratio of TRAP stimulated response over media stimulated response
(mean+95%CI, n=4–20). Vaccination by FFM ME-TRAP induced IFN-c at 1 week (p=0.0246) and at 3 months (p=0.0913) after vaccination. No
significant change in gene expression was observed at any time point post vaccination in the Rabies vaccine group.
doi:10.1371/journal.pone.0008434.g001
Table 2. Mean expression of the different cytokines/markers at different time points (log copy number/HPRT).
FFM-ME-TRAP Rabies
Cytokine Time N Mean(95%CI) N Mean(95%CI) P value
IFN-c Day 0 20 1.9(0.8–1.37) 10 1.12(0.76–1.65) 0.44
1 week 20 1.62(1.08–2.42) 10 0.77(0.5–1.18) 0.02
Month 3 10 1.39(0.89–2.16) 10 1.11(0.86–1.44) 0.34
Month 9 4 0.74(0.14–3.99) 4 0.86(0.42–1.74) 0.8
FOXp3 Day 0 19 0.88(0.64–1.21) 10 0.9(0.58–1.39) 0.94
1 week 20 0.76(0.4–1.44) 10 1.07(0.74–1.55) 0.45
Month 3 10 1.15(0.88–1.5) 10 0.88(0.72–1.1) 0.1
Month 9 4 0.92(0.82–1.04) 4 0.73(0.33–1.62) 0.38
IL-10 Day 0 20 1.9(0.70–1.78) 10 1.12(0.84–1.48) 0.93
1 week 20 0.95(0.71–1.27) 10 1.32(0.73–2.39) 0.23
Month 3 10 1.08(0.83–1.41) 10 0.96(0.44–2.1) 0.74
Month 9 4 1.137(0.63–2.04) 4 0.871(0.22–3.44) 0.59
TGF-b1 Day 0 20 1.057(0.91–1.2) 10 0.943(0.76–1.17) 0.34
1 week 20 1.045(0.9–1.2) 10 0.939(0.8–1.1) 0.33
Month 3 10 1.387(0.89–2.16) 10 1.112(0.86–1.44) 0.37
Month 9 4 0.851(0.77–0.94) 3 0.836(0.36–1.95) 0.92
The mean mRNA expression levels were compared between the two vaccination groups.
doi:10.1371/journal.pone.0008434.t002
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time in both TRAP stimulated and media stimulated cells over the
3 month study period. There was a significant increase in IFN-c
gene expression in TRAP stimulated cells in the FFM ME-TRAP
vaccinated group at week 1 when compared to screening
(p=0.016, Figure 4A). There was also a significant increase in
FoxP3 mRNA expression at week 1 compared to screening in the
FFM ME-TRAP vaccinated group (p=.0084, Figure 4B). FoxP3
expression at week 1 was significantly higher in the FFM ME-
TRAP group when compared to the rabies group at week 1
(p=0.016). We then examined gene expression over time in media
stimulated cells. There was a significant increase in FoxP3 mRNA
expression at week 1 compared to screening in the FFM ME-
TRAP vaccinated group (p=.0149, Figure 5B). FoxP3 expression
at week 1 was significantly higher in the FFM ME-TRAP group
when compared to the rabies group at week 1 (p=.0068). When
examining the fold change of FoxP3 expression in TRAP
stimulated over media stimulated cells there appeared to be no
change in gene expression following vaccination (Figure 1).
However, a paired analysis of data over time reveals a non-
antigen specific increase in FoxP3 expression over the study period
(Figures 4B and 5B).
Discussion
Understanding vaccine induced immune responses in malaria
exposed populations is vital as previous malaria exposure may
affect the quality and dynamics of vaccine immunogenicity.
This study demonstrates a method of analysing cellular
responses to vaccinations that can be used on cryopreserved
samples from field trials. Responses were studied following both
experimental vaccination against malaria and a control vaccine.
We demonstrate real-time RT-PCR to be a sensitive way of
detecting cellular responses in this setting. A modest but significant
increase in IFN-c expression was observed one week after last
vaccination in the antigen-stimulated cells in subjects receiving the
FFM regimen, and this is consistent with the responses observed
by ex vivo ELISpot assays as reported earlier [21]. Although we
were able to detect vaccine induced IFN-c expression we have
found that the IFN-c ELISPOT assay is more sensitive than qPCR
for the detection of IFN-c secreting antigen specific T cells. The
ELISPOT assay can reliably detect .20 SFC/10
6 PBMC [25]
whereas we could not detect 25 IFN-c secreting T cells using the
qPCR assay. We have also found that detection of an IFN-c
secreting T cell is dependent of the quantity of viable cells tested as
measured using HPRT copy number. Although limiting the
analysis to samples with an HPRT copy number .6000 did not
alter the findings of our study (data not shown) we would use this
cut-off as a quality control step in future qPCR studies. Our
method is not as sensitive as ELISPOT for the detection of IFN-c
yet it enables the simultaneous detection of multiple genes and
from a small number of cells and is therefore a useful tool for
exploratory immunology in a field setting.
There are several known mechanisms for malaria induced
immunosupression such as, impairment of dendritic cell
function by malaria [27] and induction of T-cell regulatory
Figure 2. Correlation between IFN-c mRNA 1 week following vaccination and baseline IL10, FoxP3 and TGF-b1 mRNA. There was no
correlation between antigen specific IFN-c and A) IFN-c at screening B) IL10 at screening C) FoxP3 at screening D) TGFB at screening (n=20).
doi:10.1371/journal.pone.0008434.g002
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causal association between reduced immunogenicity and more
frequent malaria and other chronic infections. Although we did
not see any direct correlation of anti inflammatory cytokines
with vaccine immunogenicity we did observe an increase in
FoxP3 expression in both TRAP stimulated and media
stimulated cells in the FFM ME-TRAP vaccinated group from
screening to one week following final vaccination. We did not
observe an increase in FoxP3 expression in the rabies vaccinated
group, however, there were fewer incidences of parasitaemia in
the 10 rabies vaccinated children selected for our study than in
t h eF F MM E - T R A Pg r o u p .I ti st h e r e f o r ep o s s i b l et h a tt h e
increase in FoxP3 expression is driven by natural exposure to
parasites rather than by FFM ME-TRAP vaccination. In an
earlier study in this cohort, parasitaemia was associated with
suppression of natural or vaccine-induced acquisition of IFN-c
T-cell responses [29]. Others have shown that elevated levels of
FoxP3 expressing regulatory T cells are found in malaria
infected patients [30]. Although it is likely that increased FoxP3
expression in our study is linked to natural exposure to parasite
further studies are warranted to exclude the possibility of the
effect being exacerbated by malaria vaccination.
Over nine months follow-up during the original study there was
a non-significant increase in the incidence of malaria in children
who received FFM ME-TRAP [26], although this was not
sustained during an extended 18 month period of follow-up
[22]. The current study found no evidence for enhanced
production of the anti-inflammatory cytokines TGF-b1 and IL-
10 in the FFM ME-TRAP group when compared to rabies
vaccinated controls. There is increasing evidence that vaccine
efficacy is determined by not only the magnitude but the quality of
the vaccine induced T cellular immune response [31,32]. The
magnitude of the IFN-c response induced by vaccination in our
study was small. It is possible that immune regulatory mechanisms
are limiting the T cellular immune response in naturally exposed
individuals. Further investigation of regulatory T cell responses in
both malaria vaccinated and non-vaccinated children are
warranted,
Conclusions
Measurement of gene expression of a panel of key cytokines
over several timepoints by real-time RT-PCR provides a
method of monitoring cellular responses to vaccination, and
represents a method for detailed analysis of samples obtained in
a field setting.
We have seen some evidence for the induction of a FoxP3
expression in children vaccinated with FFM ME-TRAP. To
obtain a malaria vaccine that will be useful in Africa, further
vaccine studies should seek to increase the magnitude and quality
of the IFN-c immune response and investigate the induction of
regulatory T cell responses in naturally exposed populations.
Materials and Methods
Ethics Statement
This study was performed with the permission of KEMRI
National Ethics Committees, and COREC, the NHS Central
Office for Research Ethics Committees. The trial was assigned
registration number ISRCTN88335123 with the International
Standard Randomized Controlled Trial Number Register (http://
www.controlled-trials.com/isrctn/trial/. After a series of public
meetings and individual discussions parents or guardians of the
participants were assigned a screening date. On the day of
screening study information was repeated to parents or guardians
and written informed consent was obtained before study
procedures were initiated.
Study Participants
Frozen samples were obtained from children recruited in a
phase 2b malaria vaccine trial that evaluated the efficacy of the
regimen of FFM ME-TRAP in preventing episodes of clinical
malaria among 1–6 year old children in Kilifi, Kenya. Rabies
vaccine was used as a control. Peripheral blood mononuclear cells
(PBMCs) were isolated and frozen as previously described [21] at
screening, 1 week, 3 and 9 months after last vaccination. Children
for inclusion in the study were selected on the basis of the IFN-c
ELISPOT response (response range 2.5–512.5 SFC/10
6 PBMC).
Children with an IFN-c ELISPOT response .100 SFC/10
6
PBMC were preferentially selected for inclusion in the study as
these children were most likely to have a detectable change in gene
expression as measured by qPCR.
Figure 3. Correlation of qPCR with the IFN-c ELISPOT assay is
dependent on the frequency of antigen specific T cells present
and the quantity of viable cells tested. A) The qPCR detection of
IFN-c secreted by a known number’s of mouse CD8 T cell clone’s. The
detection limit is .25 and ,250 T cell clones/10
6 splenocytes. B)
Spearman’s correlation of TRAP peptide stimulated IFN-c measured by
qPCR and ELISPOT improves as the cut-off for HPRT copy number
increases. The dashed line indicates a p value of 0.05.
doi:10.1371/journal.pone.0008434.g003
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PBMCs were thawed and re-suspended at 10 million cells per
ml of media (RPMI with 10% fetal calf serum [Sigma-Aldrich,
Poole, Dorset, UK] and Penicillin-streptomycin (Invitrogen,
Paisley, UK). 1.0610
6 cells in 100 ml of media were transferred
in duplicate wells to a 96-well plate. Cells were incubated in a
37uC/5% CO2 incubator for 4 hours, then stimulated by adding
100 ml of TRAP peptide pools (TRAP derived 20-mer peptides
overlapping by 10 amino acids [33]) at 4 mg/ml (final concentra-
tion 2 mg/ml) or in 100 ml of media alone. The cultures were
incubated for a further 12 hours. Stimulation was stopped by
spinning at 1200 rpm for 5 minutes. The supernatant was
discarded and 100 ml of RNeasy RTL buffer (Qiagen, Crawley,
UK) with 10 ml beta-mercaptoethanol (VWR, Lutterworth,
Leicestershire, UK)/ml added. Cells were then stored at 220uC
before RNA extraction.
RNA Extraction
RNA was extracted from 1610
6 PBMC using RneasyH Mini
kit (Qiagen, Crawley, UK) according to the manufacturer’s
instructions.
Reverse Transcription
Reverse transcription of mRNA was performed using oligo-dt
(MWG-Biotech Milton Keynes,UK) and the OmniscriptRTH Kit
(Qiagen, Crawley, UK). Briefly, 5 ml of RNA extracted was added
to 15 ml of the reaction mix in a 1.5 ml eppendorf tube. This was
then incubated for 1–2 hours at 37uC followed by 5 mins at 94uC.
Real-Time PCR
1 ml of the template cDNA was added into the master mix with
the relevant primer make a final volume of 20 ml. Each of the
samples was run in duplicate with 2 negative controls included in
each PCR run. Hypoxanthine phosphoribosyl transferase
(HPRT) was used as the house-keeping gene and PCR data
was normalised against HPRT. Real -Time PCR was performed
using LightCyclerH (Roche) with QuantiTectHSYGRH Green kit
(Qiagen, Crawley, UK). Primers were targeted towards the
following sequences;
FOXP3 (F 59-CACTTACAGGCACTCCTCCAGG-39 and R
59-CACCGTTGAGAGCTGGTGCAT-39), TGF-b1( F 5 9-GGA-
CATCAACGGGTTCAC T-39 and R 59-CCGGTTCATGC-
CATGAATGG-39), IFN-c (F 59-ATTCGGTAACTGACTT-
GAATGTCC-39 and R 59-CTCTTCGACCTCGAAACAGC-39),
Figure 4. TRAP peptide specific IFN-c and FoxP3 mRNA expression increase in the FFM ME-TRAP vaccine group over time. A) IFN-c
mRNA expression B) FoxP3 mRNA expression C) IL10 mRNA expression D) TGF-b1 mRNA expression (n=10–20).
doi:10.1371/journal.pone.0008434.g004
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CATGGCTTTGTAGATGCC-39), HPRT (F 59-TATGGACAG-
GACTGAACGTC-39 and R 59-CTACAATGTGATGGCCT-
CCC-39) mouse IFN-c(F 59-GGGTTGTTGACCTCA AACT-
TGGCA-39 and R 59-CAGGCCATCAGCAACAACAT-39).
Cycling conditions of an initial activation step of 15 min at 95u
followed by 45 cycles of 30 s at 94u, 30 s at 60u and 1 min at
72uwere used for each primer pair.
qPCR Detection of T Cell Clones
To determine the minimum number of IFN-c secreting T cells
that could be detected by the qPCR assay a mouse T cell clone
specific for the H-2Kd-restricted pb9 CTL epitope (SYIPSAEKI)
from the circumsporozoite protein of P. berghei was expanded using
pb9 peptide loaded irradiated splenocytes from naive BALB/c
mice. After 7 days culture in MEM medium (Sigma Aldrich)
supplemented with 10% heat-inactivated FCS, 4 mM L-gluta-
mine, 100 U/ml penicillin, 100 mg/ml streptomycin sulfate,
100 mM b-mercaptoethanol and 10 U/ml IL-2 (Lymphocult
HT, Biotest) expanded T cell clones were washed and counted.
A 10 fold dilution series of pb9 T cell clones was prepared to
obtain 250,000 to 2.5 T cell clones. T cell clones were mixed with
naive splenocytes to obtain a total cell number of 1610
6. Cells
were then stimulated overnight with 10 mg/ml pb9 peptide,
pelleted and then RNA extracted for qPCR analysis as described
above.
Statistical Analysis
The mean copy number for each of genes was normalised
against the HPRT copy number for both TRAP stimulated and
media stimulated cells. The TRAP stimulated value was then
divided by media stimulated val u et og i v eaf o l dc h a n g er a t i o .
Geometric means (95% CI) were calculated from fold change
ratio at each time point. Statistical analysis was performed on
log transformed values using Student’s t test. P,0.05 was
considered significant. The results in the graphs are expressed as
log values (Stata 9
TM, Stata coorp). Paired analysis of data
points over time were performed using Wilcoxon signed rank
and correlations were performed using Spearman’s rho (SPSS
Statistics 17.0).
Figure 5. FoxP3 mRNA expression increases over the 3 month study period in media-stimulated cells from subjects in the
FFM ME-TRAP vaccine group. A) IFN-c mRNA expression B) FoxP3 mRNA expression C) IL10 mRNA expression D) TGF-b1 mRNA expression
(n=10–20).
doi:10.1371/journal.pone.0008434.g005
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